Multivariable Cox regression analysis according to the different antithombotic regimens to define (A) the composite endpoint of ICU admission, invasive mechanical ventilation, and death (B) ICU admission (C) invasive mechanical ventilation (D) in-hospital all cause mortality
aHR | 95.0% CI for aHR | |||
Lower | Upper | P value | ||
Composite of ICU admission, invasive mechanical ventilation, and death | ||||
Prophylactic anticoagulation | 0.033 | |||
Therapeutic anticoagulation | 0.84 | 0.302 | 2.336 | 0.738 |
Prophylactic anticoagulation + antiplatelet therapy | 0.505 | 0.197 | 1.296 | 0.155 |
Therapeutic anticoagulation + antiplatelet therapy | 1.434 | 0.615 | 3.344 | 0.404 |
Hypertension | 2.568 | 1.429 | 4.617 | 0.002 |
Tocilizumab | 2.132 | 1.071 | 4.244 | 0.031 |
Admission oxygen saturation | 0.954 | 0.936 | 0.973 | 0 |
Interlukin-6 | 1 | 1 | 1.001 | 0.026 |
Predicted probability anticoagulant prescription | 0.528 | 0.06 | 4.648 | 0.565 |
Predicted probability antiplatelt prescription | 1.195 | 0.282 | 5.071 | 0.809 |
ICU admission | ||||
Prophylactic anticoagulation | 0.035 | |||
Therapeutic anticoagulation | 0.831 | 0.28 | 2.466 | 0.739 |
Prophylactic anticoagulation + antiplatelet therapy | 0.566 | 0.212 | 1.515 | 0.257 |
Therapeutic anticoagulation + antiplatelet therapy | 1.569 | 0.644 | 3.821 | 0.321 |
Hypertension | 2.331 | 1.284 | 4.232 | 0.005 |
Tocilizumab | 2.308 | 1.154 | 4.619 | 0.018 |
Admission oxygen saturation | 0.953 | 0.934 | 0.971 | 0 |
Interlukin-6 | 1 | 1 | 1.001 | 0.031 |
Predicted probability anticoagulant prescription | 0.226 | 0.021 | 2.386 | 0.216 |
Predicted probability antiplatelt prescription | 1.412 | 0.32 | 6.236 | 0.649 |
Invasive mechanical ventilation | ||||
Prophylactic anticoagulation | 0.005 | |||
Therapeutic anticoagulation | 0.629 | 0.15 | 2.628 | 0.525 |
Prophylactic anticoagulation + antiplatelet therapy | 0.07 | 0.014 | 0.351 | 0.001 |
Therapeutic anticoagulation + antiplatelet therapy | 0.359 | 0.099 | 1.309 | 0.121 |
Gender | 5.02 | 1.911 | 13.182 | 0.001 |
Hypertension | 3.343 | 1.259 | 8.876 | 0.015 |
Steroids | 439943.283 | 0 | . | 0.978 |
Admission oxygen saturation | 0.888 | 0.858 | 0.919 | 0 |
Predicted probability anticoagulant prescription | 0.005 | 0 | 0.177 | 9.004 |
Predicted probability antiplatelt prescription | 135.695 | 7.786 | 2365.045 | 0.001 |
D-dimers | 1.136 | 0.994 | 1.297 | 0.061 |
Interlukin-6 | 1.001 | 1 | 1.001 | 0.001 |
In hospital all cause mortality | ||||
Prophylactic anticoagulation | 0.014 | |||
Therapeutic anticoagulation | 0.126 | 0.028 | 0.573 | 0.007 |
Prophylactic anticoagulation + antiplatelet therapy | 0.41 | 0.103 | 1.634 | 0.206 |
Therapeutic anticoagulation + antiplatelet therapy | 0.113 | 0.028 | 0.449 | 0.002 |
Weight | 0.974 | 0.949 | 1 | 0.048 |
Hypertension | 3.684 | 1.211 | 11.209 | 0.022 |
Steroids | 73168.344 | 0 | . | 0.982 |
Tofacitinib | 2.516 | 0.872 | 7.263 | 0.088 |
Anticoagulation admission | 3.716 | 1.099 | 12.571 | 0.035 |
Admission oxygen saturation | 0.965 | 0.937 | 0.994 | 0.017 |
Predicted probability anticoagulant prescription | 0.947 | 0.058 | 15.533 | 0.97 |
Predicted probability antiplatelt prescription | 6.004 | 0.641 | 56.244 | 0.116 |
Interlukin-6 | 1 | 0.999 | 1.001 | 0.877 |
This Cox regression analysis is adjusted on anticoagulation and antiplatelet regimen, age, smoker, weight, gender, hypertension, dyslipidemia, diabetes, coronary artery disease, steroids, tofacitinib, anticoagulation on admission, immunosuppressant, antiplatelet use on admission, inpatient prescription of any of the following medication, azithromycin, fondaparinux, remdesivir, tocilizumab, oxygen saturation on admission, D-dimers, CRP and interleukin 6, in addition to propensity scores predicted probability of anticoagulant or antiplatelet prescription.
aHR, adjusted hazard ratio; ICU, intensive care unit.